JAKARTA, KOMPAS.com – The Covid-19 vaccine manufactured by Oxford – AstraZeneca has been approved for emergency use or emergency use authorization (EUA) of the Medicines and Healthcare products Regulatory Agency (MHRA). The UK government has also given regulatory approval to the MHRA’s permit for use.
Foreign Minister Retno Marsudi also said that in this way, the Food and Drug Administration (BPOM) would be easier to issue licenses for this type of vaccine in Indonesia.
“Yesterday we received news that the EUA for AstraZeneca has been provided by MHRA UK, this is good news for all of us,” said Retno during a press conference for the arrival of the Covid-19 vaccine phase II from Sinovac, Thursday (31/12/2020).
Retno explained that the MHRA is one of the authorities that has strict regulations related to clinical trials of the Covid-19 vaccine. In addition, MHRA also has a relationship with BPOM.
“Through this reliance mechanism, the EUA issuance process for the AstraZenica vaccine in Indonesia will be easier. The results of the EUA in the UK can be used as a basis. review to be issued by EUA in Indonesia, “said Retno.
He also said that BPOM has coordinated with various parties and institutions both in Indonesia and abroad to accelerate the process of issuing usage permits.
“Of course this will never be compromised, regarding the safety, effectiveness, and quality aspects of the vaccine,” said Retno.
Previously, today the Covid-19 vaccine from a pharmaceutical company from China, Sinovac, of 1.8 million doses arrived at Soekarno-Hatta Airport.
The arrival of the vaccine is the second stage after the delivery of Phase I of 1.2 million doses of vaccine on December 6, 2020. Thus, there are already 3 million doses of vaccine in Indonesia.
The vaccine that has just arrived will be sent to PT Bio Farma (Persero) in Bandung using an envirotainer transported by truck. In the truck there is also a cold room with a temperature of 2-8 degrees Celsius.
After the arrival of the phase II vaccine, Indonesia will also receive 15 million doses of vaccine in an unfinished condition from Sinovac. Later, the vaccine will be manufactured by Bio Farma.
“In the near future, it is hoped that as many as 15 million doses of vaccine blots from Sinovac which will then be manufactured by Bio Farma will also arrive in Indonesia,” he said.